Ras inhibitors
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- REVOLUTION MEDICINES INC
- Filing Date
- 2025-10-21
- Publication Date
- 2026-06-04
AI Technical Summary
Current drug discovery efforts have been largely unsuccessful in targeting the undruggable Ras proteins, which are implicated in approximately 30% of human cancers, with only two agents approved for the K-Ras G12C mutant, highlighting the need for new molecular modalities to modulate Ras protein function.
Formation of a high-affinity three-component complex between Ras proteins and the cytosolic chaperone cyclophilin A, creating a new binding pocket that sterically occludes interactions with downstream effector molecules, thereby inhibiting oncogenic signaling.
This approach provides a novel mechanism to inhibit Ras proteins, potentially offering therapeutic benefits for cancers driven by various Ras mutations, including those resistant to existing treatments.